Nothing Special   »   [go: up one dir, main page]

WO1998027113A3 - Melanocortin derivatives for specific binding of melanocortin receptor 3, 4 or 5 - Google Patents

Melanocortin derivatives for specific binding of melanocortin receptor 3, 4 or 5 Download PDF

Info

Publication number
WO1998027113A3
WO1998027113A3 PCT/NL1997/000703 NL9700703W WO9827113A3 WO 1998027113 A3 WO1998027113 A3 WO 1998027113A3 NL 9700703 W NL9700703 W NL 9700703W WO 9827113 A3 WO9827113 A3 WO 9827113A3
Authority
WO
WIPO (PCT)
Prior art keywords
melanocortin
derivatives
specific binding
receptor
receptors
Prior art date
Application number
PCT/NL1997/000703
Other languages
French (fr)
Other versions
WO1998027113A9 (en
WO1998027113A2 (en
WO1998027113A8 (en
Inventor
Roger Antonius Hendricus Adan
Johannes Peter Henri Burbach
Willem Hendrik Gispen
Original Assignee
Rudolf Magnus Inst For Neurosc
Seed Capital Investments
Roger Antonius Hendricus Adan
Johannes Peter Henri Burbach
Willem Hendrik Gispen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rudolf Magnus Inst For Neurosc, Seed Capital Investments, Roger Antonius Hendricus Adan, Johannes Peter Henri Burbach, Willem Hendrik Gispen filed Critical Rudolf Magnus Inst For Neurosc
Priority to CA002275442A priority Critical patent/CA2275442A1/en
Priority to JP52756598A priority patent/JP2001506996A/en
Priority to EP97950498A priority patent/EP0946595A2/en
Priority to AU53480/98A priority patent/AU5348098A/en
Publication of WO1998027113A2 publication Critical patent/WO1998027113A2/en
Publication of WO1998027113A3 publication Critical patent/WO1998027113A3/en
Publication of WO1998027113A8 publication Critical patent/WO1998027113A8/en
Publication of WO1998027113A9 publication Critical patent/WO1998027113A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)

Abstract

The invention provides novel peptides derived from the group of hormones including ACTH. These so-called melanocortins can target different receptors which often have different localizations on several tissues. The presently invented peptides are useful for targeting receptors in the nervous system in an agonistic manner. Pharmaceutical compositions and uses are also disclosed.
PCT/NL1997/000703 1996-12-17 1997-12-17 Melanocortin derivatives for specific binding of melanocortin receptor 3, 4 or 5 WO1998027113A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002275442A CA2275442A1 (en) 1996-12-17 1997-12-17 Melanocortin derivatives for specific binding of melanocortin receptor 3, 4 or 5
JP52756598A JP2001506996A (en) 1996-12-17 1997-12-17 Melanocortin derivatives for specific binding of melanocortin receptor 3, 4 or 5
EP97950498A EP0946595A2 (en) 1996-12-17 1997-12-17 Melanocortins
AU53480/98A AU5348098A (en) 1996-12-17 1997-12-17 Melanocortins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96203567 1996-12-17
EP96203567.1 1996-12-17

Publications (4)

Publication Number Publication Date
WO1998027113A2 WO1998027113A2 (en) 1998-06-25
WO1998027113A3 true WO1998027113A3 (en) 1998-08-06
WO1998027113A8 WO1998027113A8 (en) 1999-09-02
WO1998027113A9 WO1998027113A9 (en) 1999-11-04

Family

ID=8224709

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL1997/000703 WO1998027113A2 (en) 1996-12-17 1997-12-17 Melanocortin derivatives for specific binding of melanocortin receptor 3, 4 or 5

Country Status (6)

Country Link
EP (1) EP0946595A2 (en)
JP (1) JP2001506996A (en)
CN (1) CN1246868A (en)
AU (1) AU5348098A (en)
CA (1) CA2275442A1 (en)
WO (1) WO1998027113A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE9900497A (en) 1997-04-15 2000-06-15 Csir Pharmaceutical compositions having an appetite suppressant action
ES2304345T3 (en) 1999-03-29 2008-10-16 THE PROCTER & GAMBLE COMPANY LEGANDOS OF THE RECEIVER OF MELANOCORTINA.
WO2001030808A1 (en) * 1999-10-27 2001-05-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor-ligand binding
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
US6693165B2 (en) 2000-01-18 2004-02-17 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
GB0012370D0 (en) * 2000-05-22 2000-07-12 Quadrant Holdings Cambridge Peptoids
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
AU2002238106A1 (en) 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
JP2004534851A (en) 2001-07-11 2004-11-18 パラチン テクノロジーズ インク． Linear and cyclic peptides specific for the melanocortin receptor
MXPA05011830A (en) 2003-05-09 2006-01-26 Novo Nordisk As Peptides for use in treating obesity.
AU2004275928B2 (en) 2003-09-30 2010-03-11 Novo Nordisk A/S Melanocortin receptor agonists
BRPI0506864A (en) 2004-01-21 2007-05-29 Novo Nordisk As method for conjugating peptides, conjugated peptide, compound and pharmaceutically acceptable salts, prodrugs and solvates thereof, pharmaceutical composition, use of a compound, and method for treating disease
JP5628796B2 (en) 2008-06-09 2014-11-19 パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. Melanocortin receptor-specific peptide for the treatment of impotence
AU2010259008C1 (en) 2009-06-08 2016-04-21 Palatin Technologies, Inc. Melanocortin receptor-specific peptides
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (en) 2009-06-08 2011-01-31 Astrazeneca Ab SPECIFIC PEPTIDES FOR MELANOCORTIN RECEPTORS
EA201290295A1 (en) 2009-11-23 2013-01-30 Палатин Текнолоджиз, Инк. SPECIFIC TO MELANOCORTIN-1 RECEPTOR LINEAR PEPTIDES
EA021897B1 (en) 2009-11-23 2015-09-30 Палатин Текнолоджиз, Инк. Melanocortin-1 receptor-specific cyclic peptides
US8263781B2 (en) 2009-12-18 2012-09-11 Janssen Pharmaceutica Nv Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators
KR20130001242A (en) 2010-02-17 2013-01-03 얀센 파마슈티카 엔.브이. Aminothiazolones as estrogen related receptor-alpha modulators
US8426604B2 (en) 2010-02-17 2013-04-23 Janssen Pharmaceutica Nv Aminothiazolones as estrogen related receptor-alpha modulators
US20130012432A1 (en) 2010-02-26 2013-01-10 Novo Nordisk A/S Peptides for Treatment of Obesity
BR112012021231A2 (en) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh method for enhancing plant yield, plant, construct, use of a construct, method for producing a transgenic plant, collectable parts of a plant, products derived from a plant, use of a nucleic acid and method for producing a product
WO2011149841A1 (en) 2010-05-25 2011-12-01 Janssen Pharmaceutica Nv SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-α MODULATORS
CA2888277C (en) 2012-10-19 2023-09-05 Txp Pharma Gmbh Alpha- and gamma-msh analogues
RU2016142145A (en) 2014-04-22 2018-05-22 ТиЭксПи ФАРМА ГМБХ PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE (PROBES)
JP2020514365A (en) 2017-03-15 2020-05-21 ノヴォ ノルディスク アー／エス Bicyclic compound capable of binding to melanocortin 4 receptor
US20210221867A1 (en) 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022460A1 (en) * 1993-04-05 1994-10-13 University Patents, Inc. Diagnosis and treatment of erectile dysfunction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022460A1 (en) * 1993-04-05 1994-10-13 University Patents, Inc. Diagnosis and treatment of erectile dysfunction

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CODY, WAYNE L. ET AL: "Reversed-phase high-performance liquid chromatography studies of.alpha.-MSH fragments", J. CHROMATOGR. (1984), 314, 313-21 CODEN: JOCRAM;ISSN: 0021-9673, 1984, XP002066332 *
R.A.H. HADAN ET AL.: "Identification of antagonists for melanocortin MC3, MC4 and MC5 receptors", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 269, no. 3, 15 April 1994 (1994-04-15), UTRECHT, NL, pages 331 - 337, XP002066333 *

Also Published As

Publication number Publication date
CA2275442A1 (en) 1998-06-25
AU5348098A (en) 1998-07-15
WO1998027113A9 (en) 1999-11-04
JP2001506996A (en) 2001-05-29
CN1246868A (en) 2000-03-08
WO1998027113A2 (en) 1998-06-25
WO1998027113A8 (en) 1999-09-02
EP0946595A2 (en) 1999-10-06

Similar Documents

Publication Publication Date Title
WO1998027113A8 (en) Melanocortin derivatives for specific binding of melanocortin receptor 3, 4 or 5
WO1999033859A3 (en) Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
ZA981627B (en) Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
ZA9711537B (en) Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
IL125928A0 (en) Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and pharmaceutical compositions for inhibiting the same
WO1998005363A3 (en) Polypeptides having a single covalently bound n-terminal water-soluble polymer
EP1803733A3 (en) Use of a polypeptide comprising the extracellular domains of IL-20RA and IL-20RB for the treatment of inflammation
WO2002024909A3 (en) Receptor nucleic acids and polypeptides
WO2001083547A3 (en) Anti-inflammatory compounds and uses thereof
WO1998018497A3 (en) Contrast agents
WO2000023464A3 (en) Zinc finger binding domains for gnn
WO1996037605A3 (en) Anti sense oligonucleotides for blocking ige receptor synthesis
WO2001023412A3 (en) Methods of screening for agents which inhibit aggregation of polypeptides
WO2003002602A3 (en) Nogo and nogo receptor derived peptides for t-cell mediated neuroprotection
AUPP589598A0 (en) Novel peptides
IL135688A0 (en) Human checkpoint kinase, hcds1, compositions and methods
WO1998058957A3 (en) Disulfide cross-linked glycoprotein hormone analogs, their preparation and use
WO2000018801A3 (en) Ncam binding compounds
WO2000042031A3 (en) Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
AU7216498A (en) Inhibitors of the urokinase receptor
EP0784979A3 (en) Obesity protein formulations
WO1999031128A3 (en) Human tumor necrosis factor-r2-like proteins
EP0784982A3 (en) Obesity protein formulations
WO1998030190A3 (en) Colon cancer KH-1 and N3 antigens

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97181332.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2275442

Country of ref document: CA

Ref document number: 2275442

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997950498

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1998 527565

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 53480/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 09331287

Country of ref document: US

AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 25/98 UNDER (30) REPLACE "AT" BY "EP"

WWP Wipo information: published in national office

Ref document number: 1997950498

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 2-6 AND 8-10, DESCRIPTION, REPLACED BY CORRECTED PAGES 2-6 AND 8-10; PAGES 11 AND 12, CLAIMS, REPLACED BY CORRECTED PAGES 11 AND 12

WWW Wipo information: withdrawn in national office

Ref document number: 1997950498

Country of ref document: EP